Dr Reddys Laboratories (RDY) Net Income Attributable to Noncontrolling Interests (2009 - 2026)
Dr Reddys Laboratories' Net Income Attributable to Noncontrolling Interests came in at -$1.21 million for fiscal Q2 2027 (quarter ended Sep 30, 2026), compared with -$1.19 million a year earlier.
Powered by 
Analysis
Dr Reddys Laboratories (RDY) Net Income Attributable to Noncontrolling Interests (2009 - 2026) Analysis & Trends
Over the trailing twelve months to Sep 30, 2026, Dr Reddys Laboratories reported Net Income Attributable to Noncontrolling Interests of -$4.36 million; for FY2026 (ended Mar 31, 2026), it was -$4 million.
- Going back by fiscal year, Net Income Attributable to Noncontrolling Interests was $8 million in FY2025.
- The five-year range for quarterly Net Income Attributable to Noncontrolling Interests is -$2.27 million (fiscal Q3 2026) to $10.29 million (fiscal Q2 2025).
- Business Quant data shows RDY's Net Income Attributable to Noncontrolling Interests at -$918,960 (Q1 2027), $43,757 (Q4 2026) and -$2.27 million (Q3 2026) in the three fiscal quarters before Q2 2027.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCI Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,225.92 Bn | 1,199.53 Bn | 20.46 Bn | - |
| 2 | Johnson & Johnson | 669.87 Bn | 589.73 Bn | 17.30 Bn | - |
| 3 | AbbVie | 514.17 Bn | 482.18 Bn | 13.12 Bn | 2.00 Mn |
| 4 | Merck | 363.03 Bn | 325.97 Bn | 13.19 Bn | 2.00 Mn |
| 5 | Novartis Ag | 314.10 Bn | 287.34 Bn | - | - |
| 6 | Astrazeneca | 290.83 Bn | 264.72 Bn | 13.26 Bn | -1.00 Mn |
| 7 | Amgen | 247.70 Bn | 199.36 Bn | 7.58 Bn | - |
| 8 | Gilead Sciences | 206.67 Bn | 181.78 Bn | 6.73 Bn | - |
| 9 | Pfizer | 166.55 Bn | 113.91 Bn | 12.56 Bn | 10.00 Mn |
| 10 | Dr Reddys Laboratories | 12.37 Bn | 11.71 Bn | 472.93 Mn | -1.21 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -1.21 Mn |
| Jun 30, 2026 | -918,959.97 |
| Mar 31, 2026 | 43,756.64 |
| Dec 31, 2025 | -2.27 Mn |
| Sep 30, 2025 | -1.19 Mn |
| Jun 30, 2025 | -958,146.34 |
| Mar 31, 2025 | -762,170.25 |
| Dec 31, 2024 | -1.13 Mn |
| Sep 30, 2024 | 10.29 Mn |
| Dec 31, 2017 | 51.67 Mn |
| Sep 30, 2017 | 44.33 Mn |
| Jun 30, 2017 | 9.17 Mn |
| Mar 31, 2017 | 9.66 Mn |
| Dec 31, 2016 | 69.77 Mn |
| Sep 30, 2016 | 44.07 Mn |
| Jun 30, 2016 | 18.89 Mn |
| Mar 31, 2016 | -3.26 Mn |
| Dec 31, 2015 | -728,595.12 |
| Sep 30, 2015 | -123,271.43 |
| Jun 30, 2015 | -221,055.63 |
API Access
Dr Reddys Laboratories Net Income Attributable to Noncontrolling Interests API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=RDY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-non-controlling-interests", "ticker": "RDY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=RDY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();